drugset
drugset / Trial / NCT01705483

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

NCT01705483 ↗

Phase 1 Terminated 21 enrolled Astellas Pharma Global Development, Inc.
Non-randomizedSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.

Timeline

Start
2012-08-28
Primary completion
2014-06-11
Completion
2014-06-11

Outcome

Outcome not reported

Stopped: “Based on the results of the Phase 1 data, the company decided not to pursue the development of this drug at this time.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP9853 Unknown — Oral
Subject Docetaxel Small molecule — Intravenous
Subject Paclitaxel Small molecule — Intravenous

Indications

No indication recorded.